Countertransference as Clinical Data: A PMHNP Field Guide
Countertransference is more than discomfort — for new PMHNPs, it's clinical data. A practical framework to spot it, name it, and use it safely.
Real talk about psychopharmacology, clinical confidence, and building a practice you love — from Lindsay and the Fellowship faculty.
More Articles
Countertransference is more than discomfort — for new PMHNPs, it's clinical data. A practical framework to spot it, name it, and use it safely.
Lithium still works. The monitoring has changed. Here's the 2026 protocol PMHNPs need — baseline labs, dosing targets, and the GLP-1 era interactions.
The PAX-D trial showed pramipexole reduced treatment-resistant depression symptoms by week 12. Here's what PMHNPs need to know about dosing, monitoring, and clinical use.
A 2026 JAMA Psychiatry RCT found clozapine outperformed second-line options after one failed antipsychotic in first-episode psychosis. Here's what PMHNPs should know about early clozapine use, post-REMS monitoring, and building prescribing confidence.
ProlivRx is the first FDA-approved at-home neuromodulation for treatment-resistant depression. Here's what PMHNPs need to know about prescribing it.
Older adults are the fastest-growing population in psychiatric practice, and standard adult prescribing approaches can be dangerous in this group.
Psychiatric emergencies happen in outpatient settings. PMHNPs need protocols for managing acute suicidal ideation, severe agitation, psychotic...
Every psychiatric patient deserves systematic substance use screening, but many PMHNPs lack a structured protocol. This guide provides a step-by-step...
Prescribing psychiatric medications for children and adolescents requires different pharmacological considerations, monitoring protocols, and risk-benefit...
PTSD pharmacotherapy has evolved well beyond first-line SSRIs. This guide covers the updated evidence for prazosin, second-generation antipsychotic...